A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), Resistance Training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients - ACCeRT Study

<p>Abstract</p> <p>Background</p> <p>Cancer cachexia is a syndrome of progressive weight loss. Non-small cell lung cancer patients experience a high incidence of cachexia of 61%. Research into methods to combat cancer cachexia in various tumour sites has recently progre...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Rogers Elaine S, MacLeod Roderick D, Stewart Joanna, Bird Stephen P, Keogh Justin WL
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMC 2011-11-01
Saila:BMC Cancer
Sarrera elektronikoa:http://www.biomedcentral.com/1471-2407/11/493
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak